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Progression of diabetic nephropathy. Diabetic nephropathy is a clinical syndrome character-
Background. Diabetic nephropathy is a major cause of renal ized by persistent albuminuria, arterial blood pressure
failure. The decline in glomerular filtration rate (GFR) is highly elevation, a relentless decline in glomerular filtration
variable, ranging from 2 to 20, with a median of 12 mL/min/
rate (GFR), and a high risk of cardiovascular morbidityyear. The risk factors of losing filtration power (progression
and mortality [1]. This major life-threatening complica-promoters) have not been clearly identified. Furthermore, in-
tion develops in approximately 35% of type 1 diabeticformation on optimal arterial blood pressure, glycemic control,
and cholesterol levels are lacking. patients [2, 3]. Diabetic nephropathy is a leading cause
Methods. We measured GFR with 51Cr-EDTA plasma clear- of end-stage renal disease. However, the decline in GFR
ance technique, blood pressure, albuminuria, glycosylated he- is highly variable, ranging from 2 to 20 mL/min/year
moglobin A1c, and serum cholesterol every year for seven years [4–6]. The risk factors for losing filtration power, that(range 3 to 14 years) in 301 consecutive type 1 diabetic patients
is, the so-called progression promoters, have not beenwith diabetic nephropathy recruited consecutively during 1983
studied extensively. Hypertension and proteinuria con-through 1997. Diabetic nephropathy was diagnosed clinically
if the following criteria were fulfilled: persistent albuminuria tribute to the progressive loss of renal function, while
.200 mg/min, presence of diabetic retinopathy, and no evi- other progression promoters, for example, glycemic con-
dence of other kidney or renal tract disease. In total, 271 pa- trol and lipids, are still debatable as reviewed by Rossing
tients received antihypertensive treatment at the end of the [7]. The identification of progression promoters is impor-observation period.
tant for the creation of new powerful treatment modal-Results. Mean arterial blood pressure was 102 6 0.4 (SE)
ities impeding the development of end-stage renal dis-mm Hg. The average decline in GFR was 4.0 6 0.2 mL/min/year
and even lower (1.9 6 0.5 mL/min/year) in the 30 persistently ease. The aim of our prospective observational study,
normotensive patients, none of whom had ever received antihy- started in 1983, was to evaluate the impact of several
pertensive treatment (P , 0.01). A multiple linear regression putative progression promoters in a consecutive cohort
analysis revealed a significant positive correlation between the of 301 type 1 diabetic patients with diabetic nephropathy,decline in GFR and mean arterial blood pressure, albuminuria,
who had serial measurements of glomerular filtrationglycosylated hemoglobin A1c, and serum cholesterol during
performed and at least three years of follow-up. In addi-follow-up (R2adj 5 0.29, P # 0.001). No threshold level for blood
tion, we strived to obtain information on optimal arterialpressure, glycosylated hemoglobin A1c, or serum cholesterol
was demonstrated. A two-hit model with mean arterial blood blood pressure, glycemic control, and cholesterol levels
pressure and glycosylated hemoglobin A1c below and above the in relationship to loss of kidney function.
median values (102 mm Hg and 9.2%, respectively) revealed a
rate of decline in GFR of only 1.5 mL/min/year in the lowest
stratum compared with 6.1 mL/min/year in the highest stratum METHODS
(P , 0.001).
PatientsConclusions. The prognosis of diabetic nephropathy has
improved during the past decades, predominantly because of Since 1983, at Steno Diabetes Center, all type 1 dia-
effective antihypertensive treatment. Genuine normotensive betic patients with nephropathy have had their kidney
patients have a slow progression of nephropathy. Several modi- function monitored with one yearly determination of
fiable variables have been identified as progression promoters.
GFR. The data are kept in a diabetic nephropathy regis-
try, from which we included all type 1 diabetic patients
who had a minimum of three years of follow-up (N 5Key words: renal failure, proteinuria, glycemic control, type 1 diabetes
301). The recruitment period for our prospective cohortmellitus, antihypertensive treatment, blood pressure control, glomeru-
lar filtration rate, diabetic nephropathy. study ended in 1997. Diabetic nephropathy was diag-
nosed clinically if the following criteria were fulfilled:Received for publication May 11, 2000
persistent albuminuria .200 mg/min in at least two outand in revised form August 29, 2000
Accepted for publication September 1, 2000 of three consecutive 24-hour urine collections, presence
of diabetic retinopathy, and the absence of any clinical orÓ 2001 by the International Society of Nephrology
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laboratory evidence of other kidney or renal tract disease munoassay (r 5 0.99) [12] was documented before chang-
ing the methods. The method used for measurement of[8]. All patients took at least two daily injections of insulin
and had a diabetic diet containing 45 to 55% carbohy- glycosylated hemoglobin A1c from venous blood samples
has also changed over the years: From 1983 to 1988,drates, 30 to 35% fat, and 15 to 20% protein. No sodium
or protein restrictions were applied during the study. A high-performance liquid chromatography (HPLC) ion
exchange [14] and isoelectric focusing [15] were used.total of 271 patients were treated with antihypertensive
medication during the whole or the major part of the These methods have a normal range of 4.1 to 6.1% and
4.1 to 6.4%. Thereafter, glycosylated hemoglobin A1cfollow-up period, 179 patients predominantly with angio-
tensin-converting enzyme (ACE) inhibitors. Patients were was measured with HPLC (Bio-Rad Diamat, Richmond,
CA, USA) with a normal range of 4.1 to 6.4%. Theclassified as taking a class of antihypertensive agent if
the drug was prescribed for more than 50% of their correlations between this method and the two previous
methods were r 5 0.983 (N 5 194) and r 5 0.931 (N 5follow-up time. Seventeen percent of the patients re-
ceived monotherapy. Forty-seven percent received two 119), respectively. Finally, from 1994, an HPLC-based
method was used (Bio-Rad Variant). The normal rangeagents. Thirty percent received three agents, and 6%
were treated with four or more antihypertensive drugs. remained unchanged (4.1 to 6.4%), and the coefficient
of correlation between the latter and present methodA stepped-care approach for antihypertensive treatment
was applied. Before 1991, it included selective b blockers, was r 5 0.993 (N 5 161). Serum cholesterol was mea-
sured with standard laboratory techniques, and thediuretics, and vasodilators. After 1991, it included ACE
inhibitors, diuretics, calcium channel blockers (mainly method was unchanged during the study. Arterial blood
pressure was measured at each visit with a standard mer-dihydropyridines), and b blockers. During the whole fol-
low-up period, we strived to keep our patients’ blood cury sphygmomanometer and appropriate cuff size. The
measurements were performed twice, on the right arm,pressure below 140/90 mm Hg. Thirty patients remained
normotensive without antihypertensive treatment before after at least 10 minutes of rest in the supine position and
were averaged. Diastolic blood pressure was recordedor during the observation period, that is, genuine normo-
tensive patients. The local ethical committee approved at the disappearance of Korotkoff sounds (phase V).
Arterial hypertension was diagnosed according to thethe experimental design, and all patients gave their in-
formed consent. World Health Organization’s criteria ($160/95 mm Hg)
until 1995 and thereafter according to the American Dia-
Procedures betes Associations criteria $140/90 mm Hg [16]. All
patients visited the outpatient clinic every three to fourAll investigations were made on the same day between
8 a.m. and 1 p.m. The patients had their normal breakfast months during the study. Blood glucose concentration,
glycosylated hemoglobin A1c, albuminuria, blood pres-and usual medication at least one hour before the proce-
dure, during which the patients rested in a supine posi- sure, and body weight were monitored, and the insulin
dose and antihypertensive treatment were adjusted.tion. During the investigation period, the patients drank
approximately 150 to 200 mL of tap water per hour. Retinopathy was assessed after pupillary dilation by
ophthalmoscopy and from 1991 by fundus photographyThe GFR measurement was performed 3 to 24 times
(median 8) in each patient during a follow-up period of and graded: nil, simplex, or proliferative diabetic retinop-
athy.3 to 14 years (median 7). GFR was measured after a
single intravenous injection of 3.7 MBq 51Cr-EDTA by
Statistical analysesdetermination of the radioactivity in venous blood sam-
ples taken 180, 200, 220, and 240 minutes after the injec- Results are expressed as means and SE, means and
SD being used for descriptive information. Albuminuriation [9]. The mean variability in GFR of each patient
from day to day was 4%. Results are standardized for is given as median (range) and logarithmically trans-
formed before analysis because of the positively skewed1.73 m2 body surface, using the patient’s surface area at
the start of the study throughout. distribution. In each patient, all measurements per-
formed during the entire follow-up period were used toAlbuminuria was measured in timed urine collections,
obtained during the four-hour clearance period. Before calculate the mean values. A linear regression analysis,
least-square method, was used to determine the rate of1984, the urinary albumin concentration was measured
by radial immunodiffusion [10], from 1984 to 1990 by decline in GFR for each patient.
In normally distributed variables, a comparison be-radioimmunoassay [11], and from 1990 it was determined
by enzyme immunoassay [12]. The assays had a sensitiv- tween groups was performed by an unpaired Student
t test. In non-normally distributed continuous variables,ity of 2, 0.5, and 1.1 mg/L and a coefficient of variation
of 8, 9, and 8%, respectively. A very close correlation a Mann–Whitney test was used for comparison between
groups. A multiple linear regression analysis with back-between radial immunodiffusion and radioimmunoassay
(r 5 0.98) [13] and radioimmunoassay and enzyme im- ward selection was performed with decline in GFR as
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Table 1. Characteristics of type 1 diabetic patients suffering from diabetic nephropathy at baseline, and clinical and laboratory data during
the follow-up period
Total No antihypertensive therapy Antihypertensive therapya
N 5 301 N 5 30 N 5 271
Baseline
Sex M/F 192/109 16/14 176/95
Age yearsb 36611 35610 36611
Age at onset yearsb 1469 1369 1469
Duration of diabetes yearsb 2268 2267 2268
Height cmb 17268 17368 17269
Retinopathy simplex/proliferative 99/202 15/15 84/187h
Smoking yes/no 164/137 20/10 144/127
Systolic blood pressure mmHgb 140619 129614 141619f
Diastolic blood pressure mmHgb 8569 7969 8669f
Mean arterial blood pressure mmHgb 103611 9669 104610f
Albuminuria lg/minc 629 (45–6177) 368 (204–1694) 691f (45–6177)
Glycosylated hemoglobin A1c %b 9.361.4 8.961.2 9.461.5
Glomerular filtration rate mL/min/1.73m2 89628 106620 87628f
During follow-up periodd
Rate of decline in glomerular filtration rate mL/min/yeare 4.0 (0.2) 1.9 (0.5) 4.3 (0.3)g
Systolic blood pressure mmHge 140 (0.8) 131 (1.9) 141 (0.9)f
Diastolic blood pressure mmHge 82 (0.5) 77 (1.0) 83 (0.4)f
Mean arterial blood pressure mmHge 102 (0.4) 95 (1.1) 102 (0.5)f
Albuminuria lg/minc 557 (13–6939) 384 (124–2358) 585 (13–6939)h
Glycosylated hemoglobin A1c %e 9.3 (0.1) 8.9 (0.2) 9.3 (0.1)h
Serum cholesterol mmol/Le 5.7 (0.1) 5.0 (0.1) 5.8 (0.1)f
Observation time yearsc 6.7 (3.0–14.0) 7.0 (3.4–13.3) 6.6 (3.0–14.0)
Some patients with previously persistent albuminuria receiving antihypertensive treatment had baseline albuminuria below 200 mg/min.
a These patients received antihypertensive treatment during the whole or the major part of the follow-up period
Data are: b means 6 SD, c median (range), e means (SE)
d In each patient, all measurements performed during the entire follow-up period were used to calculate mean/median values
f P , 0.001 as compared with patients receiving no antihypertensive therapy
g P # 0.01 as compared with patients receiving no antihypertensive therapy
h P , 0.05 as compared with patients receiving no antihypertensive therapy
dependent variable, including all variables with P , 0.10 3 to 14) years, the mean rate of decline in GFR was
4.0 6 0.2 mL/min/year. The 30 genuine normotensivein univariate analyses. A two-factor analysis of variance
was used to evaluate the two hit models. The calculations patients had a significantly lower rate of decline in glo-
merular filtration as compared with the hypertensive pa-were performed with a commercially available program,
tients (1.9 6 0.5 vs. 4.3 6 0.3 mL/min/year, respectively,SPSS 8.0 (SPSS Inc., Chicago, IL, USA).
P , 0.01). However, the mean arterial blood pressureTo evaluate whether there were nonlinear effects of
was also significantly lower in the normotensive groupthe variables on the decline in GFR, we extended the
compared with the patients receiving antihypertensivelinear regression model to a model with one change point
medication (95 6 1 vs. 102 6 0.5 mm Hg, P , 0.001).for each variable at a time. By varying the change point,
In addition, albuminuria, glycosylated hemoglobin A1c,we could estimate the position of the change point (thresh-
and serum cholesterol were lower in the normotensiveold) and test whether inclusion of a change point improved
patients (P , 0.05). When comparing the 30 genuinethe model [17]. These calculations were performed by
normotensive patients with previously hypertensive pa-the freely available software R (http://www.ci.tuwien.
tients, who on antihypertensive treatment obtained theac.at/R).
same level of blood pressure (N 5 102), there was noA P value ,0.05 (two-sided) was considered statisti-
difference in the decline in kidney function (1.9 6 0.5cally significant.
vs. 2.5 6 0.3 mL/min/year, respectively, NS). The rate
of decline in GFR in patients predominantly treated with
RESULTS ACE inhibitors versus patients mainly treated with other
The characteristics of the patients at baseline are blood pressure-lowering agents did not differ signifi-
shown in Table 1. The demographic and clinical data of cantly (4.5 6 0.3 vs. 3.8 6 0.4 mL/min/year, respectively,
the patients in the genuine normotensive group and in NS). Furthermore, there was no difference in mean arte-
the group receiving antihypertensive treatment were rial blood pressure values between patients predomin-
alike. However, the latter group had higher arterial antly treated with ACE inhibitors as compared with pa-
blood pressure and albuminuria and lower GFR (P , tients mainly treated with other blood pressure-lowering
agents (103 6 0.6 vs. 102 6 0.7 mm Hg, NS). No statistical0.001). During the investigation period of seven (range
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Table 2. Multiple linear regression analysis of progression promoters in type 1 diabetic patients suffering from diabetic nephropathy
Variable Slope (95% CI) P value
Dependent variable
Rate of decline in GFR mL/min/year
Independent variables
Mean arterial blood pressure per 10 mmHg 1.18 (0.59–1.77) , 0.001
Albuminuria log10 2.04 (1.07–3.01) , 0.001
Hemoglobin A1c % 0.73 (0.36–1.10) , 0.001
Serum cholesterol mmol/L 0.66 (0.27–1.05) 0.001
R2 adj.: 0.29
Not included in the model are age, sex, height, grade of retinopathy, smoking, and class of antihypertensive treatment.
significant differences in any of the other progression mm Hg systolic and 90 mm Hg diastolic. Correspond-
ingly, 202 patients (75%; 69 to 80%) had a mean arterialpromoters were demonstrated between these two groups
(data not shown). blood pressure below 107 mm Hg during follow-up.
A univariate analysis of demographic, clinical, and
laboratory parameters revealed a significant positive cor-
DISCUSSIONrelation between the decline in GFR (dependent vari-
Our long-term prospective observational study in 301able) and systolic (r 5 0.27, P , 0.001), diastolic (r 5
type 1 diabetic patients suffering from diabetic nephrop-0.37, P , 0.001) and mean arterial blood pressure (r 5
athy revealed that the prognosis of diabetic nephropathy0.39, P , 0.001), albuminuria (r 5 0.41, P , 0.001),
has improved during the past decades. Genuine normo-glycosylated hemoglobin A1c (r 5 0.30, P , 0.001), and
tensive patients have a slow rate of decline in GFR.serum cholesterol (r 5 0.32, P , 0.001) during the study.
Furthermore, several modifiable variables—that is, arte-Men had a significantly higher rate of decline in GFR
rial blood pressure, albuminuria, glycemic control, andthan women (4.4 6 0.3 vs. 3.4 6 0.4 mL/min/year, P ,
serum cholesterol—act as progression promoters. Fi-0.04). After adjustment for other progression promoters,
nally, except for albuminuria, no statistical threshold ef-the rate of decline in GFR was similar in men (4.1 6
fect on the decline in GFR of any of the identified pro-0.3 mL/min/year) and in women (4.0 6 0.4 mL/min/year,
gression promoters was demonstrated.NS). Smoking, degree of retinopathy, height, age, class
To minimize selection bias and maximize generaliz-of antihypertensive treatment, and baseline GFR had no
ability, all type 1 diabetic patients with diabetic nephrop-predictive value. When these variables were examined in
athy according to the well-defined criteria [8] who hadcombination by multiple linear regression analysis, the
a minimum of three years of follow-up on their kidneysignificant predictors of decline in GFR were high values
function were enrolled in our prospective cohort study.of mean arterial blood pressure, albuminuria, glycosy-
To obtain a valid determination of the rate of decline inlated hemoglobin A1c, and serum cholesterol (r 5 0.54,
GFR the following requirements should be fulfilled: Ther2adj 5 0.29, P # 0.001; Table 2).
applied GFR method should have good accuracy and pre-The relationship between the rate of decline in GFR
cision, and repeated measurements of GFR (,every 6 toand each of the four previously mentioned progression
12 months) should be performed. The observation periodpromoters separated in quintiles is shown in Figure 1.
should be extended to at least two years [18]. TheseExcept for albuminuria (threshold 436 mg/min, P , 0.01),
requirements were fulfilled in our study. A major strengthnone of the other potentially modifiable progression pro-
in prospective cohort studies (such as ours) is a long-termmoters showed a significant threshold, suggesting that
follow-up period of an unselected, well-defined groupthe best fit of the data is linear or curve linear.
of patients, which maximize the generalizability of theA two-hit model with mean arterial blood pressure
(previously demonstrated to be a modifiable progression findings. The limitations are that the identified progres-
sion promoters can only be documented as modifiablepromoter) combined with each of the three previously-
mentioned potentially modifiable risk factors for losing risk factors in randomized clinical intervention trials,
and interpretation of the impact of different treatmentfiltration power is shown in Figure 2.
Of the 271 patients treated with antihypertensive modalities is limited, since different categories of pa-
tients can receive different therapy.agents, 139 patients (51%; 95% CI, 45 to 57) achieved
a systolic blood pressure below 140 mm Hg during fol- The natural history of diabetic nephropathy is charac-
terized by arterial blood pressure elevation and a relent-low-up. In 234 patients (86%; 82 to 90%), diastolic blood
pressure was below 90 mm Hg, whereas 128 patients less decline in GFR of approximately 12 mL/min/year
[4–6]. Data from studies evaluating the rate of decline(47%; 41 to 53%) achieved a blood pressure below 140
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Fig. 1. Impact of mean arterial blood pressure, glycosylated hemoglobin A1c, albuminuria, and serum cholesterol on the decline in GFR (P ,
0.001 for each factor).
in GFR are presented in Table 3. While the original the glomerular capillaries and therefore to glomerular
capillary hypertension. Studies in experimental diabeticstudies did not include patients on antihypertensive
treatment, such treatment was applied in 90% of our animals [28, 29] and more recently in humans [30] have
documented intrarenal hypertension, and have stressedpatients, and we demonstrated a much slower rate of
decline in GFR (4 mL/min/year). A retrospective analy- the importance of this hemodynamic phenomenon in the
initiation and progression of diabetic and nondiabeticsis of 158 type 1 diabetic patients with nephropathy has
revealed results nearly identical to the present findings glomerulopathies [31].
Impaired autoregulation of glomerular pressure and[19]. Several prospective antihypertensive treatment tri-
als have documented a beneficial effect on albuminuria, systemic blood pressure elevation induce distention–
contraction of glomeruli. These alterations are associatedrate of decline in GFR, progression to end-stage renal
disease, and survival in type 1 diabetic patients suffering with mesangial cell stretch, that in turn stimulates the
synthesis and deposition of extracellular matrix materialfrom diabetic nephropathy [8, 20–25]. Thus, arterial blood
pressure seems to have a rather complex relationship with leading to mesangial expansion and glomerulosclerosis
[32, 33]. In diabetic glomeruli, the mechanical stretchdiabetic nephropathy: nephropathy raising blood pressure
and blood pressure accelerating the course of nephropa- effect on extracellular matrix material synthesis is mark-
edly aggravated by the presence of hyperglycemia [33].thy. This acceleration may be at least partly due to im-
paired/abolished autoregulation of GFR [26, 27], leading Proteinuria is usually considered a marker of the ex-
tent of glomerular damage, but studies in various experi-to enhanced transmission of systemic blood pressure to
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sive treatment on the long-term decline in kidney func-
tion in diabetic and nondiabetic nephropathies [43–45].
Development of overt diabetic nephropathy has for
many years been regarded as “a point of no return” in
relationship to glycemic control as reviewed by Rossing
[7]. However, this statement is based on studies using
inappropriate methods for monitoring kidney function
(serum creatinine), long-term glycemic control (blood
glucose), and often, very few patients were studied.
Applying better research techniques and in some studies
a larger number of type 1 diabetic patients, a significant
impact of glycemic control on progression of nephropa-
thy has been found [19, 37, 46], as also documented in
our study. Furthermore, pancreas transplantation can
reverse the lesions of diabetic glomerulopathy, but rever-
sal requires more than five years of normoglycemia [47].
Our study demonstrated that elevated serum choles-
terol acts as an independent progression promoter in
diabetic nephropathy. This finding supports the concept
advocated by Moorhead et al [48] that hyperlipidemia
promotes progression in chronic renal diseases once an
initial event has damaged the glomerular capillary wall,
thereby allowing passage of lipids and lipoproteins into
the mesangium. Several short-term studies dealing with
a limited number of diabetic patients have failed to dem-
onstrate a beneficial effect of lipid lowering treatment
on the surrogate endpoint: albuminuria [7]. Long-term
trials applying a principal endpoint such as the decline
in GFR are still lacking.
A renoprotective effect of ACE inhibitors above and
beyond the effect of blood pressure lowering has been
demonstrated in some clinical trials [23, 24], while others
have failed to demonstrate an additional non-hemody-
namic effect of ACE inhibition [abstract; Tarnow et al,
Diabetologia 42(Suppl 1):A275, 1999] [25]. In our long-Fig. 2. The decline in GFR divided according to median of mean arte-
rial blood pressure combined with median albuminuria, glycosylated term prospective observational study, we could not dem-
hemoglobin A1c, and serum cholesterol. Within each combination of risk onstrate a renoprotective effect of treatment with ACE
factors, a comparison of the four different strata revealed a significant
inhibitors in comparison with other antihypertensivedifference (P , 0.001).
treatment modalities. However, the present study was
not designed to evaluate this concept since ACE inhibi-
tors were not available until 1989. In addition, as our
mental animal models suggest that proteinuria per se study did not use a randomized design, different patient
may contribute to glomerular and tubulointerstitial le- categories could in fact receive different antihyperten-
sions [34]. Our study suggests that albuminuria is an sive treatment modalities.
independent risk factor for progression of diabetic ne- Previous studies have documented a relationship be-
phropathy, a finding that confirms and extends previous tween the degree of glomerular lesions and GFR and
results in normotensive and hypertensive type 1 and type 2 progression of diabetic nephropathy in type 1 and type 2
diabetic patients with nephropathy [19, 35–39]. Similarly, diabetic patients [49–51]. Furthermore, a progressive loss
proteinuria is a progression promoter in nondiabetic ne- of intrinsic ultrafiltration capacity has been shown to be
phropathies [40, 41]. Furthermore, intervention that has the predominant cause of the declining GFR in type 2
ameliorated the progression of diabetic nephropathy has diabetic patients with nephropathy [39]. The combined
always been associated with a reduction in proteinuria contribution from the previously identified renal struc-
as reviewed by Parving [42]. Finally, it should be recalled tural lesions and the present demonstrated progression
that initial reduction in albuminuria is the best clinical promoters explains the vast majority of progression in
diabetic nephropathy. Unfortunately, the role of geneticguideline predicting a beneficial effect of antihyperten-
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Table 3. Observational studies and clinical trials on progression of diabetic nephropathy in type 1 diabetic patients with and without
antihypertensive treatment (AHT)
DGFR Mean arterial blood pressure
mL/min/year mmHg
Follow-up
Authors Study design N years No AHT NonACE-I ACE-I No AHT NonACE-I ACE-I
Mogensen et al [4] Observational, retrospective 10 2.8 10.9 — — 121a — —
Parving et al [5] Observational, prospective 14 2.2 9.0 — — 111 — —
Viberti et al [6] Observational, retrospective 13 2.5 14.4 — — 109b — —
Bjo¨rck et al [23] Randomized trial 40 2.2 — 5.6 2.0 — 103 102
Lewis et al [24] Randomized trial 409 2.7 — 10.8c 8.0c — 100 96
Elving et al [25] Randomized trial 29 2.0 — 3.7 4.9 — 101d 100d
Tarnow et ale Randomized trial 48 4.0 — 5.5 6.5 103 100
Mulec et al [19] Observational, retrospective 158 8.0 — 3.8f — 102f
Present study Observational, prospective 301 6.7 1.9 3.8 4.5 95 102 103
Glomerular filtration rate (GFR) determination was based on renal or plasma clearance of filtration markers. Blood pressure measurements were based on mean
of values during follow-up.
a MABP at end of the study
b MABP at entry to the study
c Creatinine clearance, GFR calculated from percentage decrease per year using the formula: y 5 y0 3 exp(2kt), decline in GFR per year from baseline to mean
follow up of 2.7 years
d MABP during last 6 months of follow up
e Abstract [Tarnow et al., Diabetologia 42(Suppl 1): pA275, 1999]
f Antihypertensive treatment varied throughout the follow-up period
factors cannot be evaluated in our study, since systemati- REFERENCES
cal collection of DNA first began in 1993. 1. Parving H, Østerby R, Ritz E: Diabetic nephropathy, in The
Kidney, edited by Brenner BM, Levine S, Philadelphia, W.B.The available data suggest that multifactorial interven-
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